Program

Designed for clinicians, scientists, and all other members of the cancer care and research community, the 2019 Gastrointestinal Cancers Symposium will feature a wide array of multidisciplinary topics and expert faculty will offer insights on the application of gastrointestinal advances in: cancers of the esophagus and stomach, pancreas, small bowel and hepatobiliary tract, and the colon, rectum and anus.

For trainee and early career attendees, we offer a chance to attend a Networking Luncheon, to discuss career planning and cultivating your own place in the medical community.  The meeting will also offer several other robust opportunities for networking, discussion, and face to face engagement with faculty members and other attendees.

6:30 AM-7:55 AM Complimentary Continental Breakfast
7:00 AM-7:45 AM

Rapid Abstract Session C: Cancers of the Colon, Rectum, and Anus

Mary Uan-Sian Feng, MD—Chair
University of California, San Francisco

Jeffrey A. Meyerhardt, MD, MPH, FASCO—Chair
Dana-Farber Cancer Institute/ Partners Cancer Care

Abstract 484: A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer: The ACTS-CC 02 trial.
First Author: Takao Takahashi, MD, PhD

Question and Answer

Abstract 485: Circulating tumor cell count from a blood sample for colorectal cancer (CRC) prevention: A 627-patient prospective study.
First Author: Wen-Sy Tsai

Question and Answer

Abstract 486: Total neoadjuvant therapy with short course radiation compared to concurrent chemoradiation in rectal cancer.
First Author: William Chapman Jr., MD, MPHS

Question and Answer

Abstract 487: Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided.
First Author: Jerome Galon, PhD

Question and Answer

7:00 AM-7:45 AM Breakout Session: The Latest Updates on HIPEC for Gastrointestinal Cancers

George J. Chang, MD, MS—Chair
The University of Texas MD Anderson Cancer Center

Charles A. Staley, MD
Winship Cancer Institute, Emory University
Understanding the RCT Data from HIPEC for Colorectal Cancer: An Opportunity?

Franco Roviello, MD, FACS
University of Siena
Optimal Patient Selection for HIPEC for Metastatic Gastric Cancer

Panel Question and Answer
7:00 AM-7:55 AM Poster Session C: Cancers of the Colon, Rectum, and Anus
7:00 AM-7:55 AM Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
7:55 AM-8:45 AM Welcome and Keynote Lecture: Immunotherapy—Lessons Learned From Melanoma for Application to GI Malignancies

Emily K. Bergsland, MD—Chair
University of California - San Francisco

Emily K. Bergsland, MD
University of California - San Francisco
Welcome of the Day

Siwen Hu-Lieskovan, MD, PhD
University of California, Los Angeles Medical Center

Question and Answer
8:45 AM-10:15 AM General Session 7: Innovations in Multimodality Management of Rectal Cancer

Daniel T. Chang, MD—Chair
Stanford University

Zhen J. Wang, MD—Chair
University of California San Francisco

Daniel T. Chang, MD
Stanford University
Case Presentation

Julio Garcia-Aguilar, MD, PhD
Colorectal Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center
Advances in Surgical Management of Patients with Rectal Cancer

Salma Jabbour, MD
Rutgers Cancer Institute of New Jersey
Radiotherapy for Rectal Cancer—Beyond the German Rectal Trial

Thomas J. George, MD, FACP
University of Florida Health Cancer Center
Expanding the Role of Chemotherapy for Rectal Cancer

Zhen J. Wang, MD
University of California San Francisco
Review of Post-treatment Response

Daniel T. Chang, MD
Stanford University
Current and Upcoming Clinical Trials

Panel Question and Answer
10:15 AM-10:45 AM Break
10:45 AM-12:15 PM

Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus

Michael J. Hall, MD, MS—Chair
Fox Chase Cancer Center

Sigurdis Haraldsdottir, MD—Chair
Stanford University

Abstract 480: A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.
First Author: Carl Christoph Schimanski, MD, PhD

Abstract 481: CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
First Author: Eric Xueyu Chen, MD, PhD

Michael J. Overman, MD
The University of Texas MD Anderson Cancer Center
Discussion

Abstract 482: Adjuvant HIPEC in patients with colon cancer at high risk of peritoneal metastases: Primary outcome of the COLOPEC multicenter randomized trial.
First Author: Charlotte Emma Louise Klaver, MD, BA

Abstract 483: Does a longer waiting period after neoadjuvant radiochemotherapy improve the oncological prognosis of rectal cancer? Three-year follow-up results of the GRECCAR-6 randomized multicenter trial.
First Author: Jeremie H. Lefevre, MD, PhD

Elin R. Sigurdson, MD, PhD
Fox Chase Cancer Center
Discussion

Panel Question and Answer

12:15 PM-1:45 PM Poster Session C: Cancers of the Colon, Rectum, and Anus
With Complimentary Boxed Lunch
12:15 PM-1:45 PM Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
12:30 PM-1:15 PM

Poster Walks: Cancers of the Colon, Rectum, and Anus

George A. Fisher Jr., MD, PhD—Poster Walk Leader
Stanford University

Abstract 563: A phase II study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair–proficient (MMR-p) advanced colorectal cancer.
First Author: Mark Yarchoan, MD

Abstract 564: Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.
First Author: Francesca Battaglin, MD

Abstract 589: Characterisation of chemoradiation-induced changes in immune cells and targets for personalized therapy in locally advanced rectal cancer (LARC).
First Author: Elisa Fontana, MD

Abstract 619: A systematic review and network meta-analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer.
First Author: Mohamad Bassam Sonbol, MD

Abstract 670: Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors.
First Author: Neil Howard Segal, MD, PhD

 

Marcia Cruz-Correa, MD, PhD—Poster Walk Leader
The University of Puerto Rico and MD Anderson Cancer Center

Abstract 505: Gene-specific features (MLH1, MSH2, MSH6, PMS2) of mismatch repair (MMR) protein expression and somatic mutations (muts), microsatellite instability (MSI) and tumor mutational burden (TMB) in MSI-H and MMR-mutated tumor genomic profiles (TGPs).
First Author: Michael J. Hall, MD, MS

Abstract 515: Microsatellite instability detection from plasma of colorectal cancer patients.
First Author: Jing Sun, MD, PhD

Abstract 604: Comprehensive landscape of gene amplifications (amps) in tissue and circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).
First Author: Kanwal Pratap Singh Raghav, MD, MBBS

Abstract 606: Characteristics of colorectal cancer (CRC) patients with BRCA1 and BRCA2 mutations.
First Author: Madiha Naseem, MD

Abstract 618: Timing of first surveillance colonoscopy in stage I colon cancer patients and the association with colon cancer-specific survival.
First Author: Robert Brooks Hines, PhD

1:45 PM-3:15 PM General Session 8: Applying Advances in Tumor Profiling to Patient Management

Frank A. Sinicrope, MD—Chair
Mayo Clinic

Rodrigo Jover, MD, PhD—Chair
Alicante University General Hospital

Michael J. Hall, MD, MS
Fox Chase Cancer Center
Overview of Somatic Tumor Profiling

Jeanne Tie, MD, MBBCh, FRACP
Peter MacCallum Cancer Centre; Walter and Eliza Hall Institute of Medical Research
Circulating Tumor DNA in Colorectal Cancer: From Concept to Clinic

Scott Kopetz, MD, PhD
The University of Texas MD Anderson Cancer Center
Practical Application of Molecular Subtyping in Colon Cancer

Frank A. Sinicrope, MD
Mayo Clinic
Current and Upcoming Clinical Trials

Panel Question and Answer
3:15 PM-3:30 PM Break
3:30 PM-4:30 PM General Session 9: Updates in the Treatment of Anal and Colon Cancer

Flavio G. Rocha, MD—Chair
Virginia Mason Hospital and Medical Center

Jeffrey R. Olsen, MD—Chair
University of Colorado

Case Presentation: Colon Cancer Conundrums

Case Presentation: Locally Advanced Anal Cancer

Johanna C. Bendell, MD
Sarah Cannon Research Institute/Tennessee Oncology
Medical Oncologist

Van K. Morris II, MD
The University of Texas MD Anderson Cancer Center
Medical Oncologist

Christopher L. Hallemeier, MD
Department of Radiation Oncology, Mayo Clinic
Radiation Oncologist

Heidi Nelson, MD
Mayo Clinic
Colorectal Surgeon